EMA Adopts a New Pharmaceutical Form of Selumetinib By Ogkologos - December 16, 2025 391 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR 2021 ASCO Annual Meeting Research Round Up: Advances in Genitourinary Cancers June 23, 2021 Should CAR T Cells Be Used Earlier in People with Non-Hodgkin... January 13, 2022 FDA Approves New Dosing Regimen for Cetuximab April 13, 2021 Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas December 21, 2022 Load more HOT NEWS It Might Sound Trite But… What to Know About At-Home DNA Tests for Detecting Cancer Risk People With Certain Cancers Are Almost Three Times As Likely To... Death Rates from Lung Cancer will Fall Overall in the EU...
